share_log

B. Riley Securities Initiates Coverage On Nektar Therapeutics With Buy Rating, Announces Price Target of $4

B. Riley Securities Initiates Coverage On Nektar Therapeutics With Buy Rating, Announces Price Target of $4

b. Riley證券公司對內克塔治療進行覆蓋評級,給予買入評級,並宣佈目標價爲4美元
Benzinga ·  01/08 03:37  · 評級/大行評級

B. Riley Securities analyst Mayank Mamtani initiates coverage on Nektar Therapeutics (NASDAQ:NKTR) with a Buy rating and announces Price Target of $4.

Riley證券的分析師Mayank Mamtani對內克塔治療(納斯達克:NKTR)首次評級爲買入,並宣佈價格目標爲4美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論